GlassScriptPhysician profile
Jennifer J Patterson
NPI 1083873558
$6,938.57
in general payments reported to CMS, 2019-2025
47 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $154 · 2021: $101 · 2022: $896 · 2023: $1,550 · 2024: $1,505 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,432.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.81 | 2019-2025 | |
| Novo Nordisk INC | $777.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $661.76 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $567.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $482.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.10 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Glaxosmithkline, LLC. | $328.57 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $319.61 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $197.72 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $173.20 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $148.36 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Exact Sciences Corporation | $92.15 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $91.69 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $81.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $76.61 | 2024-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.